Grateful & very excited to welcome Nicole Tuchinda, JD, MD, LLM to SLU Law! Her expertise in health justice, childhood trauma, and equity will strengthen our community and increase our impact. Read more: www.slu.edu/law/news/202... @slulaw.bsky.social @slu-official.bsky.social

SLU Honors Scholarly Works and Grant Winners: www.slu.edu/news/announc... @slu-official.bsky.social @slulaw.bsky.social @sluhealthlaw.bsky.social

My @jama.com article with Sean Tu, Dave Slade, and Timothy Bonis was recognized this week with a 2026 @slu-official.bsky.social Scholarly Works award in the Senior Faculty, Clinical Articles category! Article here: jamanetwork.com/journals/jam...

Always excited to work with #PublicHealth colleagues and with @drsinhaesq.bsky.social

Presenting with @slulaw.bsky.social @sluhealthlaw.bsky.social colleague Heather McCabe later today on "Current Developments in Public Health Law: Impact on Missouri"

Ended the semester in Patent Law at @slulaw.bsky.social with two terrific guest lectures! Prof. Sean Tu presented "Expanding Patent Portfolios and Delayed Competition for Brand-Name Drugs" Prof. Jordana Goodman presented "Patently Inequitable"

The final hours for 2026 Health Law Scholars applications are upon us. Don't miss out on your chance to submit an abstract for consideration! More information on the submission process and workshop weekend is available on our website: www.slu.edu/law/health/s...

Always a pleasure to speak to the graduating M4s at Saint Louis University School of Medicine as part of their capstone course! My talk was titled "Pharmaceutical Prescribing: Pearls and Pitfalls." #MedEd cc: @sluhealthlaw.bsky.social

A tradition like no other: for 32 years, my @slulaw.bsky.social colleague Prof. Thomas Stewart has welcomed the entire 4th year SLU School of Medicine class to our courtroom to observe a mock trial, introducing them to the nuances of medical malpractice.

Recap and 📽️📼📺: @sluhealthlaw.bsky.social 38th Annual Health Law Symposium -- A Defining Moment for Vaccine Science and Policy t.e2ma.net/share/inboun...

SLU Law Center for Health Law Studies @sluhealthlaw.bsky.social Celebrates First in the Nation Ranking in Health Care Law www.slu.edu/law/news/202...

Thanks to @doritreiss.bsky.social for live posting @nusl.bsky.social #HLC2026, and in particular, our FDA panel!

Glad to join @sbagen.bsky.social and @drsinhaesq.bsky.social on this panel at @nusl.bsky.social's annual health law conference, with very thoughtful moderation from @davidasimon.bsky.social. Thanks to @doritreiss.bsky.social for liveposting!

This was a ton of fun. (And don't worry -- I really don't care how people pronounce my name!)

Great time moderating a panel in the FDA with @sbagen.bsky.social, @rachelsachs.bsky.social, and @drsinhaesq.bsky.social at @nusl.bsky.social annual health law conference. As usual, I butchered at least one name (Sam’s)

Great discussion! cc: @sbagen.bsky.social @rachelsachs.bsky.social @davidasimon.bsky.social @nusl.bsky.social @sluhealthlaw.bsky.social

SLU Law Center for Health Law Studies Hosts 38th Annual Symposium www.slu.edu/law/news/202... @sluhealthlaw.bsky.social

The COVID-19 #pandemic featured rapid #vaccine development & distribution, heavily reliant on the U.S. private sector, with companies profiting while retaining #patent rights. Read: spkl.io/63328ALi4e Subscribe: spkl.io/63325ALi4l#pandemic#vaccine#patentdrsinhaesq.bsky.social @slulaw.bsky.social

Check out the latest from the SSRN #blog which includes a recent selection of #research on medical law. Read more: blog.ssrn.com/2026/03/24/t... #AcademicChatter #LawSky #MedSky

Ahead of Friday’s symposium, “A Defining Moment for Vaccine and Science Policy,” Prof Michael Sinha joins the SLU Law Summations podcast to discuss what’s at risk & to preview the incredible lineup of speakers. Listen now & then register to join us. @drsinhaesq.bsky.social @slulaw.bsky.social

THIS FRIDAY -- 38th Annual @sluhealthlaw.bsky.social Symposium: "A Defining Moment for Vaccine Science and Policy" Podcast with Jessica Ciccone and @slulaw.bsky.social Summations: podcasts.apple.com/us/podcast/a... Register to join us in-person or via Zoom: docs.google.com/forms/d/e/1F...

I'll be presenting at the @nusl.bsky.social Annual Health Law Conference in Boston on April 3rd, on a panel titled "The Regulatory Environment and the FDA." Looking forward to the discussion with co-panelists @sbagen.bsky.social and @rachelsachs.bsky.social and moderator @davidasimon.bsky.social!

Please join us on March 27th at @slulaw.bsky.social for the @sluhealthlaw.bsky.social 38th Annual Health Law Symposium, "A Defining Moment for Vaccine Science and Policy" Schedule here: www.slu.edu/law/health/s... Register to attend (in person or via Zoom) here: docs.google.com/forms/d/e/1F...

At the American College of Legal Medicine meeting @asulaw.bsky.social -- presented on the "Updates in FDA Law" panel with @medlawdan.bsky.social @sjquinney.bsky.social and Dr. Jack Snyder

The article traces weight loss medication history & #obesity stigma, noting a shift from personal blame to disease recognition, & argues that new drugs could reduce barriers & stigma. Read: spkl.io/63328AvH5p Subscribe: spkl.io/63322AvH5k#obesity #LawSky @drsinhaesq.bsky.social

Please join us on March 27th at @slulaw.bsky.social for the @sluhealthlaw.bsky.social 38th Annual Health Law Symposium, "A Defining Moment for Vaccine Science and Policy" Schedule here: www.slu.edu/law/health/s... Register to attend (in person or via Zoom) here: docs.google.com/forms/d/e/1F...

Terrific guest lecture by @ghorvath.bsky.social @uclawsf.bsky.social to my Drug and Device Regulation and Innovation seminar at @slulaw.bsky.social @sluhealthlaw.bsky.social on Tuesday, focused on Incremental Innovation in medical devices. Article here: scholar.smu.edu/scitech/vol2...

Catch that #$NVS ad last night? It is a form of unbranded advertising. Novartis wants men to have their PSA levels checked because the company is heavily invested in prostate cancer therapies.

I am far less confident than Novo's chief counsel that their patent will not be invalidated. Recent actions by FDA/HHS/DOJ are much more likely to protect the company's prized asset #Wegovy.

Really enjoyed having @davidasimon.bsky.social @nusl.bsky.social join my "Drug and Device Regulation and Innovation" seminar today at @slulaw.bsky.social @sluhealthlaw.bsky.social to discuss his ongoing work on medical device safety (www.safemedicaldevices.org) and Data Distortions with the class!

Submissions for the 2026 #HealthLaw Scholars Workshop are being accepted now through April 13. The strength of the workshop relies on a strong pool of submissions, so please share this call widely. Excited to celebrate our 25th year with four excellent new scholars! www.slu.edu/law/health/s...

Pleased to be listed in @heinonline.bsky.social's Scholarly Impact Rankings for Food and Drug Law! heinonline.org/HOL/scholarl...

#FenwayPark in June

Cites my piece from the Journal of Law and the Biosciences with Lisa Verity and Ana Santos Rutschman: The pressing need for FDA regulation of tattoo ink academic.oup.com/jlb/article/... Glad to see that FDA now has guidance for industry on tattoo ink safety (Oct. 2024): www.fda.gov/regulatory-i...

Nice to see industry pushing back, akin to its response to right-to-try. Essentially, "no thanks, we prefer the status quo."

Thrilled to share that I was selected to be a Fellow of @amwadoctors.bsky.social, a program that "serves to recognize and honor distinguished members of #AMWA who have accomplished outstanding achievements in science, medicine, or academia." amwa-doc.org/members/phys... cc: @sluhealthlaw.bsky.social

Read @elaineywchen.bsky.social's write-up of former top FDA drug regulator Rick Pazdur's explosive panel at STAT's event at #JPM2026 last night, moderated by @matthewherper.bsky.social. Drug makers should be more concerned by what's happening at FDA, Pazdur said. www.statnews.com/2026/01/13/r...

This semester at @slulaw.bsky.social @sluhealthlaw.bsky.social, I will be teaching Patent Law and a seminar on Drug and Device Innovation. Looking forward to it!

Now published in @uchilegalforum.bsky.social -- Vaccines for Pandemics: Lessons from COVID-19 for H5N1 and Beyond (with Alison McCarthy, SLU LAW '25) legal-forum.uchicago.edu/sites/defaul... cc: @slulaw.bsky.social @sluhealthlaw.bsky.social @ciclslulaw.bsky.social

💬 Viewpoint: Combination-only approvals for new #HIV drugs limit generic substitution and sustain high antiretroviral prices, even after key patents expire. ja.ma/4jw2Dqz

Check out our article, "Combination-Only Approvals as a Barrier to Affordable HIV Care," in this week's issue of @jama.com: jamanetwork.com/journals/jam... cc: @sluhealthlaw.bsky.social @slulaw.bsky.social @portalresearch.org @dartmouthchem.bsky.social

Now in print in this week's issue of @jama.com!

New @jama.com article written by @medlawdan.bsky.social, @drsinhaesq.bsky.social, and I. Glenn Cohen examines the FDA’s plan to approve leucovorin for some patients with autism using evidence that departs from traditional regulatory standards jamanetwork.com/journals/jam...

A lot has happened at FDA since we wrote this piece in @jama.com, but leucovorin was a harbinger of things to come.

Also my life right now. #Torts

"If high-level officials at the FDA are interested in the new use of a drug, they should lead with evidence, not with approval, and outline a process to ensure decisional integrity."

💬 Viewpoint: Approval of leucovorin for cerebral folate deficiency based on limited evidence raises concerns about weakening FDA drug approval standards and public trust. ja.ma/4asLxYh

NEW: Paper in @jama.com (me, Glenn Cohen, & @drsinhaesq.bsky.social) discusses FDA plan to approve leucovorin for new indication based on "case reports" and "mechanistic data" 1. Departure from FDA's evidentiary standards 2. May harm patients and set bad precedent jamanetwork.com/journals/jam...